IMF's Black Swan Research Initiative & #174;: ASCENT Trial

< p > Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota, discusses the exciting new Black Swan Research Initiative & reg; clinical trial: ASCENT, which stands for Aggressive Smoldering Cure Evaluating Novel Rx Transplant. < /p > < p > In the ASCENT trial (which will begin enrolling patients later this year), high-risk smoldering myeloma patients will receive intense therapy for two years. Dr. Kumar, lead investigator of the trial, says he hopes that researchers will be able to prove that it is safe to treat these patients and get them to a sustained MRD-negative status. < /p >
Source: International Myeloma Foundation - Category: Hematology Source Type: news